title: The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
abstract: With an estimated 68,000 cases each year, Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia. Vaccination against the disease is recommended for endemic populations and also for travelers at risk. Recently, a Vero cell-derived, inactivated, SA14-14-2 strain-based JE vaccine (JE-VC) became available for travelers from non-endemic regions, replacing the traditional mouse brain-derived vaccines. First licensed in 2009, JE-VC is currently available in Europe, the USA, Canada, Australia and several other countries. In 2013, the vaccine was approved by the European Medicines Agency and the US Food and Drug Administration for use in children. This review summarizes current data on the immunogenicity, safety and clinical use of JE-VC.
authors.affiliation: Haartman Institute, University of Helsinki, Helsinki, Finland.
authors.forename: Elina O
authors.initials: EO
authors.lastname: Erra
authors.forename: Anu
authors.initials: A
authors.lastname: Kantele
mesh_terms: D000818:Animals; D002522:Chlorocebus aethiops; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D004672:Encephalitis, Japanese / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014943:Global Health; D006801:Humans; D022321:Japanese Encephalitis Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology* / Q000302:isolation & purification; D013678:Technology, Pharmaceutical / Q000379:methods; D014195:Travel; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification; D014709:Vero Cells; D014776:Virus Cultivation
chemical_list: D022321:Japanese Encephalitis Vaccines; D015164:Vaccines, Inactivated
keywords: Ixiaro; JE-VC; Japanese encephalitis; Japanese encephalitis vaccine; immunogenicity; safety; traveler